Seelos Therapeutics to Participate in the Jefferies Virtual Healthcare Conference

Rhea-AI Summary

Seelos Therapeutics, Inc. (Nasdaq: SEEL) announced its participation in the Jefferies Virtual Healthcare Conference from June 2-4, 2020. Raj Mehra, Ph.D., Chairman and CEO, will conduct one-on-one meetings via conference calls. Seelos is focused on developing therapies for central nervous system disorders and rare diseases, with a portfolio targeting major conditions including Major Depressive Disorder, PTSD, and Sanfilippo syndrome. For more details on the conference and Seelos' initiatives, visit their website.

News Market Reaction – SEEL

+2.77%

1 alert

+2.77% News Effect

On the day this news was published, SEEL gained 2.77%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

NEW YORK, May 12, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it will participate in the Jefferies Virtual Healthcare Conference, June 2-4, 2020.

Raj Mehra, Ph.D., Chairman and CEO, will host 1x1 meetings via conference calls.

For additional information about the Jefferies Virtual Healthcare Conference: https://www.jefferies.com/IdeasAndPerspectives/Conferences/325/060220

About Seelos Therapeutics:

Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system (CNS) disorders and other rare diseases. The Company's robust portfolio includes several late-stage clinical assets targeting indications including Acute Suicidal Ideation and Behavior (ASIB) in Major Depressive Disorder (MDD) or Post-Traumatic Stress Disorder (PTSD), Sanfilippo syndrome, Parkinson’s Disease, other psychiatric and movement disorders plus orphan diseases.

For more information, please visit our website: http://seelostherapeutics.com, the content of which is not incorporated herein by reference.

Contact Information:

Anthony Marciano
Head of Corporate Communications
Seelos Therapeutics, Inc. (Nasdaq: SEEL)
300 Park Ave., 12th Fl
New York, NY 10022
(646) 293-2136
anthony.marciano@seelostx.com
https://seelostherapeutics.com/
https://twitter.com/seelostx
https://www.linkedin.com/company/seelos

FAQ

What is Seelos Therapeutics' participation in the Jefferies Virtual Healthcare Conference?

Seelos Therapeutics, Inc. will participate in the Jefferies Virtual Healthcare Conference from June 2-4, 2020.

Who is hosting the one-on-one meetings for Seelos at the conference?

Raj Mehra, Ph.D., Chairman and CEO of Seelos Therapeutics, will host the one-on-one meetings.

What is the focus of Seelos Therapeutics?

Seelos Therapeutics focuses on developing therapies for central nervous system disorders and rare diseases.

What conditions does Seelos Therapeutics target?

Seelos Therapeutics targets conditions such as Major Depressive Disorder, PTSD, Sanfilippo syndrome, and Parkinson’s Disease.

Where can I find more information about Seelos Therapeutics?

More information about Seelos Therapeutics can be found on their website at seelostherapeutics.com.